{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.73","upperLimit":"9.00","value":"1.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"PFS was measured from the time of treatment initiation until the time of progressive disease (PD) or death due to any cause for patients with an event, or until the time of last follow-up for patients who were progression free.","dispersionType":"Full Range","groups":[{"description":"Recurrent/progressive DIPG patients who were treated with the \"3 times/week, three weeks on, one week off\" schedule.","id":"OG000","title":"Stratum 1"}],"paramType":"MEDIAN","populationDescription":"Recurrent/progressive DIPG patients who were enrolled on stratum 1 and received at least one dose of panobinostat were included in the analysis. Per the associated protocol objective, all dose levels on stratum 1 were combined to estimate the PFS for this stratum.","reportingStatus":"POSTED","timeFrame":"From date on treatment until date of PD or death due to any cause or date of last follow-up","title":"Progression-free Survival (PFS) in Stratum 1","type":"SECONDARY","unitOfMeasure":"months"}